Lynparza 150mg Tablet

About Lynparza 150mg Tablet

Lynparza 150mg Tablet contains Olaparib, a targeted anticancer medication that belongs to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is used in the treatment of certain cancers, including pancreatic cancer and prostate cancer, either as a standalone therapy or in combination with other anticancer medications. Olaparib works by blocking PARP enzymes that cancer cells use to repair damaged DNA, helping to slow cancer growth and promote the destruction of cancer cells. Patients should immediately contact their healthcare provider if they experience symptoms such as shortness of breath, chest pain, rapid heartbeat, fever, persistent cough, or wheezing, as these may indicate serious side effects requiring prompt medical attention. Regular blood tests are essential before and during treatment because Lynparza 150mg Tablet may lower red blood cell, white blood cell, and platelet counts, increasing the risk of anemia, infections, and bleeding complications. Before starting treatment, patients should inform their doctor about any history of lung, liver, kidney, or heart disease, as these conditions may require additional monitoring. Lynparza 150mg Tablet is not recommended during pregnancy because it may harm an unborn baby and increase the risk of miscarriage. Women of childbearing potential should undergo a pregnancy test before treatment and use effective contraception during therapy and for at least six months after the final dose. Breastfeeding should be avoided during treatment, as it is not known whether Olaparib passes into breast milk. Regular medical monitoring and adherence to treatment recommendations are essential to ensure the safe and effective use of Lynparza 150mg Tablet in managing pancreatic and prostate cancer.